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httpcense.Abstract Background: Bronchial hyperreactivity (BHR) has been described in COPD. Inhaled
corticosteroids (ICS) are used in the treatment of asthma, but the beneﬁcial effects of steroid
treatment in COPD are debatable. It has been suggested that inhaled corticosteroids are more likely
to have beneﬁcial effects in patients with COPD with more severe bronchial hyperresponsiveness.
Aim of the work: To investigate whether airway responsiveness to methacholine predicts
response to add-on ICS treatment.
Subjects and methods: The study included 50 COPD patients stage I and stage II according to
GOLD classiﬁcation based on lung function and reversibility test. All cases were subjected to writ-
ten informed consent, through history talking and clinical examination, chest X-ray, ECG and lab-
oratory tests and methacholine challenge test. Then all patients were assessed by pulmonary
function test, Clinical COPD Questionnaire (CCQ) and modiﬁed medical research council
(MMRC) dyspnea scale. We added budesonide 800 mg daily with the previous medication for
6 months then patients were reevaluated again by the same tools used in the last visit.
Results: Our study showed that among 50 COPD patients with GOLD I or GOLD II classiﬁca-
tion 24 (48%) patients were positive for methacholine challenge test. Cases with positive methacho-
line test showed signiﬁcant improvement regarding both CCQ and MMRC dyspnea scale with ICS
treatment with no signiﬁcant difference between both groups regarding pulmonary function tests.
Conclusion: The present study concluded that the presence of BHR to methacholine identiﬁes
patients with mild to moderate COPD who are likely to respond to ICS treatment.
ª 2014 The Egyptian Society of Chest Diseases and Tuberculosis. Production and hosting by Elsevier
B.V.Open access under CC BY-NC-ND license.01649587.
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Chronic obstructive pulmonary disease (COPD), a common
preventable and treatable disease, is characterized by persistent
airﬂow limitation that is usually progressive and associated
with an enhanced chronic inﬂammatory response in the air-
ways and the lung to noxious particles or gases. Exacerbationsis. Production and hosting by Elsevier B.V.
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352 M. Hantera, H. Abdel-Haﬁzand comorbidities contribute to the overall severity in individ-
ual patients [1].
It is indeed rare to ﬁnd a case of ‘pure’ COPD in the clin-
ical setup. There are often patients in whom clinical picture
overlaps with other respiratory disorders especially asthma.
Consequently there are no rigid criteria to deﬁne and catego-
rize COPD. One reason for this might be the existence of dif-
ferent clinical phenotypes of the disease. COPD presenting
with bronchial hyperresponsiveness is possibly, one such
phenotype [2].
Bronchial hyperresponsiveness (BHR) is deﬁned as an
‘‘excessive bronchial narrowing and manifests itself as an exag-
gerated bronchoconstrictor response of the airways to various
inhaled stimuli’’ [3]. Bronchial hyperreactivity (BHR) has been
described in COPD [4], and it has been suggested that this in-
creased response to provocative stimuli may be involved in the
deterioration of lung function [5]. Characteristics of the BHR
in COPD are not fully understood because of differences in
methods and dose schedules of the provoking agent used by
various investigators.
Inhaled corticosteroids (ICS) are used in the treatment of
asthma, but the beneﬁcial effects of steroid treatment in COPD
are debatable. The improvements in lung function parameters,
which are characteristic of steroid treatment in asthma, have
not been unequivocally found in patients with COPD [6–7].
It has been postulated that, if steroids are important in the
treatment of COPD, they act via downregulation of cytokine
and adhesion molecule expression with a consequent reduction
in cell migration and activation [8]. Approximately 25% of pa-
tients with stable COPD could beneﬁt from continuous steroid
treatment [8]. It has been suggested that inhaled corticosteroids
are more likely to have beneﬁcial effects in patients with
COPD with more severe bronchial hyperresponsiveness [9].
Subject and methods
50 COPD patients GOLD I (mild) or GOLD II (moderate)
were included in the study and the diagnosis of COPD was
based on lung function and reversibility test as all patients
showed obstructive pattern and reversibility less than 12%.
Study design
This multicenter study was conducted from January 2012 until
January 2013 in outpatient clinic in both Tanta University
and Cairo University to select patients with Gold I or Gold II
and to assess bronchial hyperactivity in those patients, all the
patients were subjected to the following after taking their writ-
ten consent:
Through history taking and clinical examination, Chest
X-ray, ECG and laboratory tests, Pulmonary function test
and reversibility test and methacholine challenge test.
In methacholine challenge test we used ﬁve breath dosime-
ter protocol. After recording the baseline FEV1, the patient
takes in ﬁve deep breaths of the lowest concentration of meth-
acholine. FEV1 is recorded after the maneuvres. Higher con-
centrations of methacholine are used until fall in FEV1 is
20% or more.
The results are reported as ‘PC20’ or the concentration of
methacholine at which FEV1 declined to 20% or less. It is
interpreted as follows:PC20 > 16 mg/ml = Normal BHR
PC20 4–16 mg/ml = Borderline BHR
PC20 1.0–4.0 mg/ml =Mild BHR (Positive test)
PC20 < 1.0 mg/ml =Moderate to severe BHR [10].
We collected 50 patients diagnosed as GOLD I or Gold II
COPD patients and 24 patients of them showed positive meth-
acholine challenge test. Then all patients with positive or neg-
ative methacholine challenge test were asked to receive
tiotropium once daily for one month.
Then patients were divided into two groups: Group I with
positive methacholine challenge test (n= 24) and group II
with negative test (n= 26). Then all patients in were assessed
by Pulmonary function test, Clinical COPD Questionnaire
(CCQ) and modiﬁed medical research council (MMRC) dysp-
nea scale. We added budesonide 800 mcg daily with the previ-
ous medication.
CCQ is an individual’s measurement of symptoms and
functional state to quantify the impact of the disease on the
daily life and well-being from the patient’s point of view. It
is formed of three domains (symptoms, functional and mental
domain) [11].
CCQ is short (10 items) and easy to complete i.e. it is self-
administered. It takes patients approximately 2 min to com-
plete the questionnaire. Patients are instructed to recall their
experiences during the previous week. They respond to each
question using a 7-point scale from 0 = asymptomatic/no lim-
itation to 6 = extremely symptomatic/totally limited.
After 6 months of ICS addition patients were reevaluated
again by the same tools used in the last visit.
Results
Our study showed that among 50 COPD patients with GOLD
I or GOLD II 24 (48%) patients were positive for methacho-
line challenge test.
Base line demographic data of both groups of patients
showed no signiﬁcant difference regarding age, sex, pulmonary
function test and CCQ (Table 1).
After six months of treatment there was no signiﬁcant dif-
ference in both groups regarding pulmonary function but
group I showed signiﬁcant improvement regarding both
CCQ and MMRC dyspnea scale which is not found in group
II (Tables 2 and 3).
Discussion
This multicenter trial investigated the effect of ICSs in steroid-
naı¨ve subjects with mild to moderate COPD and BHR to
methacholine challenge. The results suggest that BHR often
is present in patients with COPD (48%). This is consistent with
Tashkin et al. [12], who found that about two-thirds of smok-
ers with mild to moderate airﬂow limitation had BHR, ex-
pressed as PC20 (provocative concentration causing 20%
decrease in FEV1). Our results also suggest that treatment with
ICS is associated with a signiﬁcant improvement in quality of
life and reduction in dyspnea index.
Six months of high-dose ICS treatment were well tolerated
but had no relevant impact on FEV1% predicted. But the im-
pact was on quality of life, subjective degree of dyspnea, and
respiratory symptoms. These results are in line with previous
Table 2 Changes in CCQ, FEV1 and FEV1/FVC with ICS treatment for 6 months.
Group I (n= 24) Group II (n= 26) T-test P-value
CCQ
Before 5.548 1.99 6.024 2.121 0.817 0.418
After 2.3 0.115 5.845 2.87 6.042 0.000*
Paired t-test (P) 0.002* 0.351
FEV1% pred
Before 83.65 16 84.24 15.15 0.134 0.894
After 85.15 14.214 86.15 12.54 0.529 0.599
Paired t-test (P) 0.670 0.725
FEV1/FVC
Before 0.63 0.11 0.64 0.15 0.267 0.790
After 0.665 0.15 0.65 0.11 0.405 0.687
Paired t-test (P) 0.318 0.441
Table 3 Changes in MMRC dyspnea scale with ICS treatment for 6 months.
MRC Group I Group II
Before After Before After
N % N % N % N %
0 11 45.83 18 75.00 13 50.00 14 53.85
1 11 45.83 2 8.33 11 42.31 9 34.62
2 2 8.33 4 16.67 2 7.69 3 11.54
X2 8.587 0.437
P-value 0.013 0.803
Table 1 Demographic data.
Group I (n= 24) Group II (n= 26) T-test P-value
Mean ±SD Mean ±SD
Age 55.87 3.155 54.425 2.155 1.904 0.062
N % N % X2 P-value
Sex
Female 2 8.3 3 11.5 0.068 0.793
Male 22 91.7 23 88.5
Gold
Gold I 5 20.83 6 23.08 0.023 0.880
Gold II 19 79.17 20 76.92
Methacholine challenge test as indicator 353trials with regard to FEV1% predicted, quality of life (SGRQ),
respiratory symptoms [13–16].
Current COPD GOLD guidelines recommend initiating
treatment with long-acting bronchodilators prior to commenc-
ing add-on ICS, and the aim of the study was to investigate
whether airway responsiveness to methacholine predicts re-
sponse to add-on ICS treatment. Monotherapy with ICS alone
is not recommended and would be of little interest to study.
Furthermore, because of their differing pharmacologic actions,
it is unlikely that tiotropium (a long-acting anticholinergic)
masked steroid-induced (anti-inﬂammatory) effects.
Several large trials examining the effects of ICS in patients
with moderate to severe COPD have shown an association with
ICS use and improvement in quality of life [15,17–19]. The
Inhaled Steroids in Obstructive Lung Disease in Europe
(ISOLDE) trial, for instance, showed a signiﬁcant reduction
in health status deterioration among patients receivinghigh-dose ICS compared with placebo [20]. In the present sub-
jects with mild to moderate COPD, those with BHR showed a
signiﬁcant improvement in quality of life after 6 months of ICS
treatment, likely because of the concomitant reduction in air-
way responsiveness to methacholine. Of note is that improve-
ment in quality of life occurred despite the relative paucity of
symptoms reported.
The Swiss Study on Air Pollution and Lung Diseases in
Adults (SAPALDIA) demonstrated that asymptomatic, or si-
lent, BHR measured by direct bronchoprovocation testing
with methacholine was an increased risk factor not only for
developing COPD but also for experiencing a new onset of
symptoms, such as shortness of breath and cough [21]. There-
fore, it can be argued that by treating BHR, symptoms and,
therefore, quality of life can also be improved. Because it has
been shown that BHR to methacholine is associated with
sputum eosinophilia, it can be further hypothesized that ICS
354 M. Hantera, H. Abdel-Haﬁzreduces an underlying eosinophilic inﬂammation and, there-
fore, improves quality of life [21]. A limitation of the study
might be the lack of data for sputum eosinophilia.
It should be mentioned that therapeutic response in pa-
tients with asthma was also observed for a paucigranulocytic
phenotype of airway inﬂammation [22]. Mast cells are consid-
ered to both inﬁltrate the bronchial epithelium in COPD and
to play an important role in the airway response to mannitol
[23]. However, sputum analysis might not be the ideal method
for detecting mast cells in bronchial airways [24].
Therefore, the present study provides evidence that the
presence of BHR to methacholine identiﬁes patients with mild
to moderate COPD who are likely to respond to anti-inﬂam-
matory medication, and challenge test in mild to moderate
COPD might be useful in selecting patients for ICS treatment.
The connection between BHR and speciﬁc inﬂammatory pro-
cesses in this subgroup needs further investigation.
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